dupilumab


( Last Updated : June 23, 2022)
Generic Name:
dupilumab
Project Status:
Pending
Therapeutic Area:
Asthma
Manufacturer:
Sanofi-aventis Canada Inc.
Call for patient/clinician input open:
Brand Name:
Dupixent
Project Line:
Reimbursement Review
Project Number:
SR0745-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
As an add-on maintenance treatment in patients aged 6 to <12 years with severe asthma with a type 2 or eosinophilic phenotype characterized by: • Symptoms that are not controlled despite optimal treatment, defined by the daily use of a medium or high dose ICS + 1 controller medication or high-dose ICS alone. • EOS ≥ 150 or FeNO ≥ 20 or allergy driven asthma. • Uncontrolled asthma having at least one severe exacerbation, defined by having experienced one or more hospitalization/emergency care visit OR treatment with a systemic corticosteroid (SCS, oral, or parenteral) in the past 12 months. • A baseline assessment of asthma symptom control using a validated asthma control questionnaire must be completed prior to initiation of dupilumab treatment.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
As an add-on maintenance treatment in patients aged 6 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma.
Date NOC Issued:
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.